2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-131162
    Chymase 97501-92-3 98%
    Chymase is a protein-digester enzyme found primarily in mast cells (MC), fibroblasts, and vascular endothelial cells. Chymase is released into the extracellular stroma in the context of inflammatory signals, tissue injury and cellular stress. Chymase is also involved in angiotensin II (Ang II) production, which is used in cardiovascular disease studies.
    Chymase
  • HY-131279
    Olmesartan ethyl ester 144689-23-6 98%
    Olmesartan ethyl ester (compound 11) is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to in the high blood pressure study.
    Olmesartan ethyl ester
  • HY-131395
    N-Acetyl-Leukotriene E4 80115-95-3 98%
    N-Acetyl-Leukotriene E4 (N-Acetyl-LTE4) is a metabolite of Leukotriene E4 (LTE4) (HY-113465), which is detected in bile and urine. N-Acetyl-Leukotriene E4 produces a vasoconstriction in the mesenteric vessels which led to reduction of blood flow to the gut.
    N-Acetyl-Leukotriene E4
  • HY-131566
    Amiquinsin hydrochloride monohydrate 7125-70-4 98%
    Amiquinsin hydrochloride monohydrate is a compound with hypotensive activity. Amiquinsin hydrochloride monohydrate is metabolized in vivo, and the major metabolite is 4-amino-6,7-dimethoxy-3-quinolinol hydrochloride hydrate.
    Amiquinsin hydrochloride monohydrate
  • HY-131696
    11-deoxy Prostaglandin F1α 37785-98-1 98%
    11-deoxy Prostaglandin F1α (11-deoxy PGF1α) is an analog of prostaglandin F1α, exhibits side effects on intestines and causes the uterine contraction. 11-deoxy Prostaglandin F1α exhibits activity as vasopressor and bronchoconstrictor.
    11-deoxy Prostaglandin F1α
  • HY-131729
    16-Phenoxy tetranor Prostaglandin A2 51639-10-2 98%
    16-Phenoxy tetranor Prostaglandin A2 is a metabolite of uprostone and an analog of the antifertility hormone PGF2α.
    16-Phenoxy tetranor Prostaglandin A2
  • HY-13209S
    Ambrisentan-d10 1046116-27-1 98%
    Ambrisentan-d10 (BSF 208075-d10; LU 208075-d10) is the deuterium labled Ambrisentan (HY-13209). Ambrisentan is a selective ET type A receptor (ETAR) antagonist.
    Ambrisentan-d10
  • HY-132190
    Hexanolamino PAF C-16 137566-83-7 98%
    Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca2+-dependent and -independent pathways. Related to platelet aggregation.
    Hexanolamino PAF C-16
  • HY-132210
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane 116673-45-1 98%
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a Ki of 0.3 µM.
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
  • HY-13221A
    BRL 54443 maleate 1197333-54-2 98%
    BRL 54443 (MALEATE) is a potent 5-HT1E/1F receptor agonist (Ki values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors.
    BRL 54443 maleate
  • HY-132583
    IONIS-DNM2-2.5Rx 2857839-05-3
    IONIS-DNM2-2.5Rx (DYM101) is an antisense agent targeting dynamin 2. IONIS-DNM2-2.5Rx has the potential for the research of centronuclear myopathy (CNM).
    IONIS-DNM2-2.5Rx
  • HY-132828
    Odatroltide 1639303-73-3 98%
    Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
    Odatroltide
  • HY-132897
    PCSK9-IN-2 2099167-44-7 98%
    PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein–protein interaction (PPI) with an IC50 value of 7.57 μM.
    PCSK9-IN-2
  • HY-13289B
    (R)-Nepicastat hydrochloride 195881-94-8 98%
    (R)-Nepicastat hydrochloride is the isomer of Nepicastat (HY-13289). Nepicastat (SYN117) is a selective，potent，and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat (SYN117) can cross the blood-brain barrier (BBB).
    (R)-Nepicastat hydrochloride
  • HY-13295S
    Vinpocetine-d5 2734920-39-7 98%
    Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
    Vinpocetine-d5
  • HY-133036
    APJ receptor agonist 1 2287153-38-0 98%
    APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC50s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure.
    APJ receptor agonist 1
  • HY-133214
    Cyclazosin hydrochloride 146929-33-1 98%
    Cyclazosin hydrochloride is an α1B-adrenergic receptor antagonist. Cyclazosin hydrochloride has high specificity for α-adrenergic receptors, with pKi values of 9.23-9.57 and 8.18-8.41 for O/1A (O/la) and OflB (alb) adrenergic receptors, respectively. However, Cyclazosin hydrochloride cannot distinguish between cloned alb and alo adrenergic receptors, which have pKi values of 9.23 and 9.28, respectively.
    Cyclazosin hydrochloride
  • HY-13338A
    (S)-Mabuterol 56707-25-6 98%
    (S)-Mabuterol is a selective β2 adrenoreceptor agonist that demonstrates blood pressure reduction and increased heart rate and contractile force in animal models.
    (S)-Mabuterol
  • HY-13338S
    Mabuterol-d9 1246819-58-8 98%
    Mabuterol-d9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the β2-adrenergic receptor.
    Mabuterol-d9
  • HY-133589
    Fulvine 6029-87-4 98%
    Fulvine is a pyrrolizidine alkaloid isolated from the seeds of Crotalaria fulva. Fulvine is hepatotoxic and can be used to induce hypertensive pulmonary vascular disease in vivo.
    Fulvine
Cat. No. Product Name / Synonyms Application Reactivity